Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP)
Publication
, Conference
Zhang, T; Howard, L; Koontz, BF; Tagawa, ST; Nagar, H; Bitting, RL; Frizzell, B; Nordquist, LT; Rasmussen, J; Winters, C; Riggan, C; Davies, C ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Howard, L., Koontz, B. F., Tagawa, S. T., Nagar, H., Bitting, R. L., … Armstrong, A. J. (2023). Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Zhang, Tian, Lauren Howard, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, et al. “Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, et al. Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Zhang, Tian, et al. “Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Nordquist LT, Rasmussen J, Winters C, Riggan C, Reyes-Martinez M, Davies C, Gray S, Newman C, Fernandez E, Harrison MR, George DJ, Wu Y, Armstrong AJ. Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences